Skip to main content

Ankylosing Spondylitis

Secukinumab Effective in Non-Radiographic Axial SpA

Aug 10, 2020

The PREVENT trial was a one year, phase III study that showed significant benefits when secukinumab (SEC) was given to patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA) for 52 weeks.



To be enrolled patients had to have inflammatory low back pain and have either

Read Article
Systematic literature finds a connection between ankylosing spondylitis (AS) and dementia (RR 1.19 [95% CI 1.01‐1.41]). From a total of 6562 articles reviewed, only 4 met criteria - analysis included 156418 pts. Cause? inflammation, inactivity?

Dr. John Cush RheumNow ( View Tweet)

Aug 03, 2020

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article
Metanalysis of 10 studies ( p534 patients) shows that exercise in ankylosing spondylitis improves pain, function and disease activity. Statistically signif improvement in pain (P<0.0001), BASDAI (P <0.00001), and BASFI (P<0.00001), but not CRP and ESR.

Dr. John Cush RheumNow ( View Tweet)

Jul 30, 2020

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
CORRONA: 477 axSpA pts showed 25% having enthesitis (3.9 sites) at enrollment.

Dr. John Cush RheumNow ( View Tweet)

Jul 21, 2020
Single center retrospective Korean study of 1280 Ankylosing Spondylitis patients (595 exposed to TNFi) showed that TNFi was associated with significantly decreased Xray change rate (mSASSS) (β=−0.112, p=0.004). https://t.co/W4j0Ckt0R2

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2020
FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis.

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2020
African-Americans with Ank Spondylitis have worse disease compared to whites. Study of 10,990 AS patients shows AA to have high frequency of anterior uveitis, hypertension, diabetes, depression, and heart disease and higher ESR and CRP levels.

Dr. John Cush RheumNow ( View Tweet)

Jul 08, 2020
#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT @52wk. Significant improvement in ASAS40, BASDAI50&amp; ASdAS-CRP ID.
Dr. John Cush RheumNow ( View Tweet)
Jul 07, 2020
UK population study shows fibromyalgia pts have a higher risk of Self harm (HR 2.06; 1.60,2.65)), RA (HR 1.59) & OA, but not ank spondylitis.

Dr. John Cush RheumNow ( View Tweet)

Jul 02, 2020
CHMP of the EMA has recommended approval of intravenous & subcutaneous formulations of CT-P13 (Remsima) for use in 5 conditions - Crohn, UC, ankylosing spondylitis, PsA & psoriasis. Remsima dose is 120 mg q 2wks regardless of body weight.

Dr. John Cush RheumNow ( View Tweet)

Jun 30, 2020

Adverse Events With Rheum Biologics Rise With Age

Jun 23, 2020

Among patients with rheumatic diseases, age and female sex were important factors associated with the development of a first adverse event after initiating biologic treatment, Spanish researchers reported.

Read Article
WHO global safety database shows increased risk of DVT & PE with tofacitinib & baricitinib, who were likely to be older with preexisting VTE risk. In EU, TOFA risk for DVT/PE was OR 2.3; BARI risk was OR 3.4.

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2020
RheumNow Podcast is Up! New FDA approvals for secuminumab, canakinumab, risk of GI perforations, tocilizumab in COVID, Weaning DMARDs/Biologics and Blacks with AS.

Dr. John Cush RheumNow ( View Tweet)

Jun 20, 2020

RheumNow Podcast – Enough Already with Weaning (6.19.20)

Jun 19, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
African-Americans with Ank Spondylitis have worse disease compared to whites. Study of 10,990 AS patients shows AA to have high frequency of anterior uveitis, hypertension, diabetes, depression, and heart disease and higher ESR and CRP levels.

Dr. John Cush RheumNow ( View Tweet)

Jun 17, 2020
Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush.

Dr. John Cush RheumNow ( View Tweet)

Jun 14, 2020

Virtual EULAR 2020 Round Up

Jun 12, 2020

In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic

Read Article

Day 3 - Top 5 from EULAR 2020

Jun 10, 2020

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA: -erosion in >=2 consecutive slices or in >=3 SIJ quadrants - fat lesions w/depth >1cm in >=1SIJ quadrant are high priority candidates @RheumNow
Olga Petryna DrPetryna ( View Tweet)
Jun 07, 2020
#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT 52wk study. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID.
Olga Petryna DrPetryna ( View Tweet)
Jun 07, 2020
#eular2020 #op0314 5 y drug-free remission (5DFR) is rare in early AxSpA: 17%pts from DESIR cohort reach 5DFR. Shorter disease duration (<1.3y), lower BASDAI&ASAS-CRP & less peripheral involv more likely to achieve DFR. Imaging and biological data did not predict DFR @RheumNow

Olga Petryna DrPetryna ( View Tweet)

Jun 07, 2020
New genome wide association study on anterior uveitis. Heritability for uveitis is 0.7, much greater than axSpA.
Dr Philip Robinson philipcrobinson ( View Tweet)
Jun 07, 2020
Sustained clinical response shown over the 10 yrs of this German study in r-axSpA and nr-axSpA pts treated with ETN. No new safety signals.
Dr. Rachel Tate uptoTate ( View Tweet)
Jun 06, 2020
×